Arovella Therapeutics (ASX:ALA) EPS (Basic): A$-0.01 (TTM As of Dec. 2025)


What is Arovella Therapeutics EPS (Basic)?

Arovella Therapeutics ASX:ALA EPS (Basic) is A$-0.01 as of Dec. 2025. The stock has 1 warning sign investors should review.

Arovella Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.01.

Arovella Therapeutics's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.01.

Arovella Therapeutics's EPS without NRI for the six months ended in Dec. 2025 was A$-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 20.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Arovella Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 49.20% per year. The lowest was -120.30% per year. And the median was 14.60% per year.

Arovella Therapeutics  (ASX:ALA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arovella Therapeutics EPS (Basic) Related Terms

Arovella Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Arovella Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arovella Therapeutics EPS (Basic) Chart

Arovella Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.02 -0.01 -0.01 -0.01

Arovella Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 -0.00 -0.01 -0.00

Arovella Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Arovella Therapeutics's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.509-0)/1097.199
=-0.01

Arovella Therapeutics's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.879-0)/1196.050
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$-0.01 mean?
Arovella Therapeutics (ASX:ALA) has a EPS (Basic) of A$-0.01 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arovella Therapeutics and its competitors.
Is Arovella Therapeutics' EPS (Basic) too high?
Arovella Therapeutics' current EPS (Basic) is A$-0.01.
How does Arovella Therapeutics' EPS (Basic) compare to VRTX and REGN?
Arovella Therapeutics' EPS (Basic) of A$-0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Arovella Therapeutics and its competitors. Arovella Therapeutics's current EPS (Basic) is A$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current EPS (Basic) of A$-0.01. The current EPS (Basic) is A$-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current EPS (Basic) is A$-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arovella Therapeutics Business Description

Other Exchanges E4NA:Germany
Address 84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.